Contributor
Richard Wang, Andrea Bernardini and Erfan Akbraian
Menu
Richard Wang, Andrea Bernardini and Erfan Akbraian
The world of orphan drugs is at the cusp of a transformation in the post COVID era. In this episode, the team discuss the impact of the pandemic on value demonstration of orphan drugs. In order to be successful, manufacturers of precision medicine will need to focus on carving out a niche for their drugs and support health systems to find the right patient for their treatment at the right time.
The team also explore the role of digital tools such as Artificial Intelligence (AI) and telemedicine in helping drugmakers optimise manufacturing and treatment delivery. This combined with a multi-stakeholder approach will provide the recipe for success for next generation`niche-busters’.
Other contributors: Richard Wang, Andrea Bernardini and Erfan Akbraian
Producer: Aparna Krishnan
